Sibtain Shabbir

Gynuity envisions a world in which each individual has access to safe and effective reproductive and maternal health care—delivered where, when, and how needed.

It is our mission to develop scientific, clinical and programmatic evidence in reproductive and maternal health and to advocate for its use, assuring that each individual benefits from the fruits of medical science and technology. We do this on a global scale through research, strategic partnerships, and communications for impact.

Our Approach

Gynuity listens to women, providers and policymakers, and works with them to create services that are safe, high quality, and person-centered. Through conversations and active collaborations, we use research to fill evidence gaps for new models of care, influence change, and advocate for improvements in policy and practice.


Our research demonstrates that simple, safe, and effective reproductive and maternal health technologies transform lives and improve outcomes for women and girls.

Policy and Practice

Through speaking, convening partners, and publishing our research, we create the synergies that trigger change in policy and practice.

Communications for Impact

Strategic communications increase the impact of our research and programmatic findings.

Latest Resources

Oral Misoprostol Alone versus Oral Misoprostol Followed by Oxytocin for Labour Induction in Women with Hypertension in Pregnancy (MOLI): Protocol for a Randomised Controlled Trial

Bracken, H., Lightly, K., Mundle, S., Kerr, R., Faragher, B., Easterling, T., Leigh, S., Turner, M., Alfirevic, Z., Winikoff, B., Weeks, A.

Clinical and Service Delivery Implications of Omitting Ultrasound Before Medication Abortion Provided Via Direct-to-Patient Telemedicine and Mail

Anger, H.A., Raymond, E.G., Grant, M., Haskell, S., Boraas, C., Tocce, K., Banks, J., Coplon, L., Shochet, T., Platais, I., Winikoff, B.
See all Resources

Ilana Dzuba, Senior Director at Gynuity, chats with media editor of the medical journal Contraception about research Gynuity and partners undertook on later first trimester medical abortion. Their conversation pivots on an award-winning article.

Listen to the Podcast (16 minutes)
One and Done Toolkit

This toolkit provides resources for providers and health care systems to introduce service delivery that allows people choosing medical abortion the option to receive an implant or injectable contraceptive at the same time as mifepristone.

View Toolkit
Reflections on 20 Years of Mifepristone

Gynuity views mifepristone abortion as a revolutionary technology with the potential to increase autonomy and choice in the reproductive realm. Here we reflect on our work to increase medical abortion access.

View Reflections
Strategic Plan 2018 - 2023

Learn about Gynuity's achievements and new programmatic directions.

Read the Strategic Plan
discover TelAbortion

The United States’ first direct-to-patient abortion with pills telemedicine service.

Visit the TelAbortion Website
browse our Image Bank

Gynuity's image bank offers illustrations that can help articulate concepts across audiences. Available for download.

View the Image Bank

Discover where to find quality assured medical abortion products.

Explore the Database
See Our Achievements

Gynuity has been at the forefront of global women’s health since 2003.

See our Achievements
TelAbortion Toolkit

Gynuity's TelAbortion Media Toolkit provides messaging and graphics for the dissemination of information about the study across media channels.

View Here
History of Mifepristone

This short film on the history of mifepristone policy in the U.S. investigates baseless FDA restrictions and claims that overstate the danger of the drug. It is a great refresher on the many barriers to medical abortion access and the burden this puts onto abortion-seekers and care providers. The film features Gynuity president Beverly Winikoff.

View Video
Self-Managed Abortion

As part of a podcast series on Self-Managed Abortion, Gynuity president Beverly Winikoff offers her insights on mifepristone – Part 3: The Abortion Pill, RU486

Listen to the Podcast